Publication Name	World Journal of Hepatology
Manuscript ID	108730
Country	Oman

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies
Manuscript Source	Invited Manuscript
All Author List	Said A Al-Busafi, Ahmed Alwassief, Ali Madian, Hassan Atalla, Mohamed Alboraie, Ashraf Elbahrawy and Mohammed Eslam
Funding Agency and Grant Number
Corresponding Author	Said A Al-Busafi, Associate Professor, FRCP (C), MD, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, PO Box: 35, Alkoudh.123, Muscat 123, Oman. busafis@squ.edu.om
Key Words	Metabolic dysfunction-associated fatty liver disease; Gut dysbiosis, Gut-liver axis; Fecal microbiota transplantation; Microbiome-based diagnostics; Bile acid metabolism; Precision medicine
Core Tip	The pathogenesis of metabolic dysfunction-associated fatty liver disease (MAFLD) is profoundly influenced by gut dysbiosis, a condition that exacerbates disease progression through mechanisms such as compromised intestinal barrier function, endotoxemia, and dysregulated bile acid metabolism. Understanding and addressing this issue is of utmost importance in the management of MAFLD. Advances in microbiome-based diagnostics, including machine learning models and microbial biomarkers, now provide non-invasive tools for early detection and risk stratification, enhancing clinical decision-making. The emergence of therapies targeting the gut-liver axis, such as probiotics, fecal microbiota transplantation, and farnesoid X receptor agonists, demonstrates significant potential in mitigating hepatic inflammation and restoring metabolic homeostasis.
Citation	<p>Al-Busafi SA, Alwassief A, Madian A, Atalla H, Alboraie M, Elbahrawy A, Eslam M. Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies. <i>World J Hepatol</i> 2025; 17(8): 108730</p>

Received	2025-04-27 03:07
Peer-Review Started	2025-04-29 00:13
To Make the First Decision
Return for Revision	2025-05-12 08:39
Revised	2025-05-26 20:34
Second Decision	2025-07-24 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-07-24 08:07
Articles in Press	2025-07-24 08:07
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-08-13 04:09

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com